As Arrowhead falters, lungs remain a tough target for RNA drugs
snippet
Safety concerns in animal tests led Arrowhead Pharmaceuticals to suspend testing of a closely watched drug for cystic fibrosis, the latest setback for an RNA-based medicine against the genetic lung disease.
Source
BioPharma Dive